BOCA RATON, FL—Nabi Biopharmaceuticals (Nasdaq:NABI) has agreed to sell its Nabi Bilogics business unit to Biotech Pharmaceuticals Corp. for $185 million.

Biotest researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has more than 1,200 employees worldwide.

Biotest has agreed to acquire the Biologics SBU’s products, including Nabi-HB [Hepatitis B Immune Globulin], and other plasma business assets, including Nabi’s state-of-the-art plasma protein production plant, and nine FDA-certified plasma collection centers across the U.S.

The acquisition also will include certain of Nabi’s Corporate Shared Services group assets and the company’s Boca Raton, Florida headquarters and other facilities, as well as the assumption of certain liabilities.

After the closing of the transaction, Nabi Biopharmaceuticals will operate its Pharmaceuticals SBU from its existing Rockville, Maryland facility, which will become its new corporate headquarters.

The company has an on-going trial with NicVAX (Nicotine Conjugate Vaccine), its innovative and proprietary investigational vaccine for nicotine addiction and the prevention of smoking relapse.

Nabi will continue its ongoing discussions and efforts to secure a strategic partner for its NicVAX and StaphVAX (Staphylococcus aureus Polysaccharide Conjugate Vaccine) programs.

Nabi also will retain the right to receive up to an additional $75 million in milestone and royalty payments related to the divestiture of PhosLo in November 2006.

On the Web: www.nabi.com

Southeast Venture Conference, February 29 – March 1, 2012 at the Ritz Carlton in Tysons Corner, VA – Where Smart Money Meets Smart People.
www.seventure.org

© 2007, TechJournal South. All rights reserved.